EP1778269A4 - Non-diabetogenic therapy using a 20kda placental growth hormone variant - Google Patents

Non-diabetogenic therapy using a 20kda placental growth hormone variant

Info

Publication number
EP1778269A4
EP1778269A4 EP05799870A EP05799870A EP1778269A4 EP 1778269 A4 EP1778269 A4 EP 1778269A4 EP 05799870 A EP05799870 A EP 05799870A EP 05799870 A EP05799870 A EP 05799870A EP 1778269 A4 EP1778269 A4 EP 1778269A4
Authority
EP
European Patent Office
Prior art keywords
diabetogenic
20kda
therapy
growth hormone
placental growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05799870A
Other languages
German (de)
French (fr)
Other versions
EP1778269A2 (en
Inventor
Peter Gluckman
Stewart Gilmour
Mark Hedley Vickers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuren Pharmaceuticals Ltd
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of EP1778269A2 publication Critical patent/EP1778269A2/en
Publication of EP1778269A4 publication Critical patent/EP1778269A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
EP05799870A 2004-07-23 2005-07-22 Non-diabetogenic therapy using a 20kda placental growth hormone variant Withdrawn EP1778269A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59079404P 2004-07-23 2004-07-23
US64946905P 2005-02-02 2005-02-02
PCT/US2005/026061 WO2006012525A2 (en) 2004-07-23 2005-07-22 Non-diabetogenic therapy using a 20kda placental growth hormone variant

Publications (2)

Publication Number Publication Date
EP1778269A2 EP1778269A2 (en) 2007-05-02
EP1778269A4 true EP1778269A4 (en) 2009-09-23

Family

ID=35786728

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05799870A Withdrawn EP1778269A4 (en) 2004-07-23 2005-07-22 Non-diabetogenic therapy using a 20kda placental growth hormone variant

Country Status (3)

Country Link
EP (1) EP1778269A4 (en)
JP (1) JP2008507559A (en)
WO (1) WO2006012525A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040406A2 (en) * 2017-08-24 2019-02-28 Ohio University Methods of treatments using growth hormone variants and compositions therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356107A2 (en) * 1988-08-19 1990-02-28 Eli Lilly And Company Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism
EP0753307A2 (en) * 1995-06-29 1997-01-15 Mitsui Toatsu Chemicals, Incorporated Human growth hormone agent for adults
WO2002101002A2 (en) * 2001-06-07 2002-12-19 Genodyssee Identification of snps the hgv-v gene

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7383298A (en) * 1997-05-13 1998-12-08 Regents Of The University Of California, The Novel antiangiogenic peptide agents and their therapeutic and diagnostic use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356107A2 (en) * 1988-08-19 1990-02-28 Eli Lilly And Company Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism
EP0753307A2 (en) * 1995-06-29 1997-01-15 Mitsui Toatsu Chemicals, Incorporated Human growth hormone agent for adults
WO2002101002A2 (en) * 2001-06-07 2002-12-19 Genodyssee Identification of snps the hgv-v gene

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CULLER F L ET AL: "Comparison of the acute metabolic effects of 22,000-dalton and 20,000-dalton growth hormone in human subjects", HORMONE AND METABOLIC RESEARCH, THIEME-STRATTON, STUTTGART, DE, vol. 20, no. 2, 1 February 1988 (1988-02-01), pages 107 - 109, XP002099021, ISSN: 0018-5043 *
VICKERS ET AL: "P-01 THE 20kDa PLACENTAL GH-V LACKS THE DIABETOGENIC AND LACTOGENIC ACTIVITIES OF GH-N WHILST RETAINING ANTI-LIPOGENIC ACTIVITY", GROWTH HORMONE AND IGF RESEARCH, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 16, 1 November 2006 (2006-11-01), pages S27, XP005832058, ISSN: 1096-6374 *

Also Published As

Publication number Publication date
JP2008507559A (en) 2008-03-13
WO2006012525A2 (en) 2006-02-02
WO2006012525A3 (en) 2006-08-24
EP1778269A2 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
HK1072908A1 (en) Growth hormone releasing peptides
AU2003251992A8 (en) Therapeutic devices for patterned cell growth
GB0416396D0 (en) Therapeutic agents
GB0419850D0 (en) Therapeutic agents
GB0403780D0 (en) Therapeutic agents
ZA200704926B (en) Modified human growth hormone
GB0419192D0 (en) Therapeutic agents
GB0423103D0 (en) Therapeutic agents
EP1778269A4 (en) Non-diabetogenic therapy using a 20kda placental growth hormone variant
GB2420976B (en) Therapeutic implant
GB0425854D0 (en) Therapeutic treatment
GB0417939D0 (en) Therapeutic agents
GB0400193D0 (en) Therapeutic agents
ZA200609395B (en) Therapeutic peptides
GB0408752D0 (en) Therapeutic treatment
GB0403779D0 (en) Therapeutic agents
GB0416934D0 (en) Therapeutic agents
GB0400196D0 (en) Therapeutic agents
GB0402918D0 (en) Therapeutic agents
GB0419594D0 (en) Therapeutic peptides
AU2009242122B2 (en) Pegylated recombinant human growth hormone compounds
AU303152S (en) Medical dressing
GB0421533D0 (en) Therapeutic use
GB0420265D0 (en) Therapeutic treatment
GB0425281D0 (en) Therapeutic treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070222

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUREN PHARMACEUTICALS LIMITED

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090824

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/27 20060101AFI20090818BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091121